Before 2007 In 1996,
Cardinal Health acquired PCI of
Philadelphia, Pennsylvania, a pharmaceutical contract packing service for commercial and clinical packaging. In 1998, Cardinal Health acquired R.P. Scherer Corporation of
Troy, Michigan for $2.2 billion; it was founded by
Robert Pauli Scherer to commercialize his innovation of
softgel encapsulation using the rotary die production process. In 1999, Cardinal Health acquired Automatic Liquid Packaging of
Woodstock, Illinois, thereby entering the sterile product market with
blow fill seal technology. In April 2002, Cardinal Health acquired Magellan Laboratories, a company that specialized in product development expertise. In October 2003, Cardinal Health acquired Gala Biotech of
Madison, Wisconsin for $15.5 million. It also acquired Intercare Group of the UK for $530 million, broadening its global capabilities in Europe.
2007–2019 In April 2007, the pharmaceutical technologies and services segment of Cardinal Health was acquired by affiliates of
The Blackstone Group and re-branded as
Catalent Pharma Solutions. In February 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore. Catalent also acquired all remaining shares for the R.P Scherer site in
Eberbach, Germany. In March 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology, a China-based company, and Relthy Laboratories in Brazil. In July 2014, Catalent became a
public company via an
initial public offering on the New York Stock Exchange, raising $870 million. In November 2014, Catalent acquired Micron Technologies, a provider of particle size engineering technologies, expanding its portfolio of drug delivery technologies. In September 2016, Catalent acquired Pharmatek Laboratories to add spray drying capabilities. In October 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with
oncology development, In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, expanding its biologic manufacturing. In July 2018, Catalent acquired Juniper Pharmaceuticals for $133 million. In March 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new
Zydis lines; changes to facilities in
Swindon, UK; and a custom suite for commercial equipment. In September 2018, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for
Parkinson's disease utilizing the Zydis delivery method. In May 2019, Catalent acquired Paragon Bioservices for $1.2 billion to expand its gene-therapy manufacturing capabilities. By October 2019, Paragon's employee count doubled since the April acquisition.
2020–present In January 2020, Catalent purchased a manufacturing facility located in
Anagni, Italy, from
Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies. In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million, to expand into cell therapy development. In 2020, Catalent partnered with multiple drugmakers, including
Pfizer,
Johnson & Johnson,
AstraZeneca, and
Moderna to provide manufacturing, vial filling and packaging capabilities for
COVID-19 vaccines. In the partnership with AstraZeneca, Catalent provided manufacturing from its Maryland facility and vial filling and packaging from its Italian facility. Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's facility in
St. Petersburg, Florida. In August 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics. That month, Catalent also acquired Bettera Holdings, a nutritional supplement company, for $1 billion to provide capability to manufacture vitamins, minerals and supplements in gummy form. In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in
Shiga, Japan. In August 2022, the company acquired Metrics Contract Services, a
contract manufacturing organization, for $475 million. In October 2022, Catalent announced a $12M expansion at a
Kansas City, Missouri facility. In January 2023, Catalent partnered with
Sarepta Therapeutics to manufacture
delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced
gene therapy candidate for the treatment of
Duchenne muscular dystrophy (DMD). In December 2024,
Novo Holdings A/S acquired Catalent for $16.5billion. As part of the transaction,
Novo Nordisk acquired three manufacturing facilities from parent Novo Holdings for $11billion to scale up production to meet the demand of
Wegovy and
Ozempic. == Financials ==